Prosecution Insights
Last updated: November 12, 2026
Application No. 18/901,679

INHALATION DEVICE

Non-Final OA §102§103§DOUBLEPATENT
Filed
Sep 30, 2024
Priority
Jul 20, 2005 — provisional 60/700,947 +6 more
Examiner
SUL, DOUGLAS YOUNG
Art Unit
3785
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Manta Devices LLC
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
326 granted / 595 resolved
-15.2% vs TC avg
Strong +56% interview lift
Without
With
+55.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
30 currently pending
Career history
631
Total Applications
across all art units

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION This office action is in response to the amendment filed 4/09/2025. As directed by the amendment, no claims have been amended, claims 1-19 have been cancelled, and claims 20-33 newly added. Thus, claims 20-33 are presently pending in this application. The present application is being examined under the pre-AIA first to invent provisions. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim(s) 20-21 and 23-26 is/are rejected under 35 U.S.C. 102(e) as being anticipated by Houzego (2007/0181123). PNG media_image1.png 304 434 media_image1.png Greyscale Regarding claim 20, Houzego discloses in the annotated fig 9 above an inhaler comprising: a replaceable dose cassette comprising top (34) (airway plate) and bottom layers (26) (insert) defining at least a portion of an air path, wherein the bottom layer (26) defines a reservoir containing a drug dose (insert (26) contains a respective dose of powder) (para [0155]), and at least a portion of the reservoir includes a curved surface (insert (26) is generally cup shaped) (para [0155], fig 9a), wherein the air path includes an air inlet (42) (para [0167]) and a restriction opposite the air inlet (42) (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]), and a diverter is located proximate the restriction and above at least a portion of the reservoir to divert at least a portion of air into the reservoir when the air is drawn through the air path (see annotated fig 9(b)); and a mouthpiece (6) fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece (6) (para [0148]). Regarding claim 21, Houzego discloses the air inlet (42) is formed between the top (34) and bottom layers (26) (see annotated fig 9(b)). Regarding claim 23, Houzego discloses a surface shaped to divert the at least a portion of air into the reservoir (26) (as shown in fig 9(b), front surface of diverter portion directs air downwardly into reservoir). Regarding claim 24, Houzego discloses at least a portion of the surface on the diverter is curved (as shown in fig 9b, portion of front surface of diverter portion is shown to be curved). Regarding claim 25, Houzego discloses the top layer and the bottom layer are movable relative to each other (as shown in figs 7a-b, bottom layer (26) is movably vertically relative to top layer (34) to open insert (26)) (para [0164]). Regarding claim 26, Houzego discloses the top layer (34) and the bottom layer (26) are movable from a closed position to an opened position (as shown in figs 7a-b, bottom layer (26) is movably vertically relative to top layer (34) to open insert (26)) (para [0164]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 22 is/are rejected under 35 U.S.C. 103 as being unpatentable over Houzego. Regarding claim 22, Houzego discloses the air path at the inlet has a 120% and 200% larger cross-sectional area than at the restriction (D) (para [0029]). Houzego does not disclose the air path is wider at the air inlet than at the restriction. However, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Houzego so that the air path is wider at the air inlet than at the restriction, as it has been held that changes in size and shape and optimization of ranges are within the level of skill of one of ordinary skill in the art. Therefore, modifying the width of the air inlet and restriction so that the air path is wider at the air inlet than at the restriction by routine experimentation would have been an obvious modification so that the cross-sectional area of the air inlet is 120% to 200% larger than the cross-sectional area of the restriction (para [0029]). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 20-21 and 23-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 3-5 of U.S. Patent No. 11,491,287 in view of Houzego. Regarding claim 20, application claim 20 differs from US patent claim 3 (and claim 1, from which claim 3 depends from) in the following respect: Application claim 20 US patent claim 3 20. (New) An inhaler comprising: (1) a replaceable dose cassette comprising top and bottom layers defining at least a portion of an air path, wherein the bottom layer defines a reservoir containing a drug dose, and at least a portion of the reservoir includes a curved surface, (2) wherein the air path includes an air inlet and (3) a restriction opposite the air inlet, and (4) wherein a diverter is located proximate the restriction and above at least a portion of the reservoir to divert at least a portion of air into the reservoir when the air is drawn through the air path; and a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece. 1. A drug delivery device comprising: (1) first and second parts moveable relative to each other from a closed position to an open position; wherein the first part defines, at least in part, a reservoir for containing a dose, the reservoir including a top, side walls and a bottom, and wherein at least a portion of the reservoir includes at least a first curved surface; wherein at least a portion of the second part fits against the first part in the closed position to seal the dose in the reservoir; (2) wherein the first and second parts, in the open position, create an air path including an air inlet to receive entering air flow and an air outlet, wherein, in the open position, the top of the reservoir is open and the bottom of the reservoir is closed, wherein the air inlet is configured to direct at least a portion of the entering air flow at the air outlet in the open position, (3) and wherein at least a portion of the air path is shaped to create a restriction. 3. The drug delivery device of claim 1 further comprising (4) at least a second curved surface located over the reservoir to divert at least a portion of the entering air flow into the reservoir. US patent claim 3 does not disclose a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece. However, Houzego teaches a respiratory device including a restriction opposite the air inlet (42) (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]), and a mouthpiece (6) fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece (6) (para [0148]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of US patent claim 2 by providing a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece as taught by Houzego in order to allow a user to inhale the medicament through a mouthpiece (Houzego, para [0007]). Regarding claims 21 and 23-26, US patent claims 1 and 3-5 discloses the limitations of application claims 21 and 23-26. Claims 27-32 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 and 3-5 of U.S. Patent No. 11,491,287. Although the claims at issue are not identical, they are not patentably distinct from each other. Regarding claim 27, application claim 27 differs from US patent claim 3 (and claim 1, from which claim 3 depends from) as follows: Application claim 27 US patent claim 3 27. (New) A dose cassette for use with an inhaler, comprising: (1) a bottom layer defining a reservoir, wherein at least a portion of the reservoir includes a curved surface; and (2) a top layer slidably movable relative to the bottom layer from a closed position to an opened position, (3) wherein the top layer and the bottom layer define at least a portion of an air path having an air inlet in the opened position to allow air to flow into the reservoir, (4) wherein the air path includes a restriction opposite the air inlet in the opened position, and (5) wherein a diverter is located proximate the restriction and above at least a portion of the reservoir in the opened position to divert at least a portion of air into the reservoir when the air is drawn through the air path. 1. A drug delivery device comprising: (2) first and second parts moveable relative to each other from a closed position to an open position; wherein (1) the first part defines, at least in part, a reservoir for containing a dose, the reservoir including a top, side walls and a bottom, and wherein at least a portion of the reservoir includes at least a first curved surface; (2) wherein at least a portion of the second part fits against the first part in the closed position to seal the dose in the reservoir; (3) wherein the first and second parts, in the open position, create an air path including an air inlet to receive entering air flow and an air outlet, wherein, in the open position, the top of the reservoir is open and the bottom of the reservoir is closed, wherein the air inlet is configured to direct at least a portion of the entering air flow at the air outlet in the open position, (4) and wherein at least a portion of the air path is shaped to create a restriction. 3. The drug delivery device of claim 1 further comprising (5) at least a second curved surface located over the reservoir to divert at least a portion of the entering air flow into the reservoir. US patent claim 3 does not disclose a restriction opposite the air inlet. However, Houzego teaches a respiratory device including a restriction opposite the air inlet (42) (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of US patent claim 2 by providing a restriction opposite the air inlet as taught by Houzego in order to provide a maximum air velocity through the pocket portion (Houzego, para [0030]). Regarding claims 28-32, US patent claims 1 and 3-5 disclose the limitations of application claims 28-32. Claims 20-21 and 23-32 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 and 7 of U.S. Patent No. 12,343,469 in view of Houzego. Regarding claim 20, application claim 20 differs from US patent claim 2 (and claim 1, from which claim 2 depends from) in the following respect: Application claim 20 US patent claim 2 20. (New) An inhaler comprising: (1) a replaceable dose cassette comprising top and bottom layers defining at least a portion of an air path, wherein the bottom layer defines a reservoir containing a drug dose, and at least a portion of the reservoir includes a curved surface, (2) wherein the air path includes an air inlet and a restriction opposite the air inlet, and (3) wherein a diverter is located proximate the restriction and above at least a portion of the reservoir to divert at least a portion of air into the reservoir when the air is drawn through the air path; and a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece. 1. A dose delivery device, comprising: (1) a lower portion and an upper portion defining a reservoir for containing a dose and including a single reservoir opening, at least a portion of the reservoir including a curved surface, and the reservoir being openable, wherein the upper portion and the lower portion define an opening mechanism movable from a closed position to an open position, wherein, with the reservoir opened, the lower and upper portions define an air flow path generally along and across at least a portion of the single reservoir opening of the reservoir from an inlet opening to an outlet opening, such that at least a portion of air in the air flow path enters the reservoir through the single reservoir opening to entrain the dose in the reservoir, and air including entrained dose exits the reservoir through the single reservoir opening and then exits the outlet opening in a direction that is not back toward the inlet opening. 2. The dose delivery device of claim 1, further comprising (3) a diverter portion proximate the outlet to divert the at least a portion of air into a lower part of the reservoir to disperse the dose in the reservoir into air flowing into and out of the reservoir. US patent claim 2 does not disclose a restriction opposite the air inlet, and a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece. However, Houzego teaches a respiratory device including a restriction opposite the air inlet (42) (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]), and a mouthpiece (6) fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece (6) (para [0148]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of US patent claim 2 by providing a restriction opposite the air inlet, and a mouthpiece fluidly coupled to the air path such that the drug dose exits the reservoir into the air path and flows through the mouthpiece as taught by Houzego in order to provide a maximum air velocity through the pocket portion (Houzego, para [0030]) and to allow a user to inhale the medicament through a mouthpiece (Houzego, para [0007]). Regarding claims 21 and 23-26, US patent claims 1-4 discloses the limitations of application claims 21 and 23-26. Regarding claim 27, application claim 27 differs from US patent claim 2 as follows: Application claim 27 US patent claim 2 27. (New) A dose cassette for use with an inhaler, comprising: (1) a bottom layer defining a reservoir, wherein at least a portion of the reservoir includes a curved surface; and (2) a top layer slidably movable relative to the bottom layer from a closed position to an opened position, (3) wherein the top layer and the bottom layer define at least a portion of an air path having an air inlet in the opened position to allow air to flow into the reservoir, wherein the air path includes a restriction opposite the air inlet in the opened position, and (4) wherein a diverter is located proximate the restriction and above at least a portion of the reservoir in the opened position to divert at least a portion of air into the reservoir when the air is drawn through the air path. 1. A dose delivery device, comprising: (1) a lower portion and an upper portion defining a reservoir for containing a dose and including a single reservoir opening, at least a portion of the reservoir including a curved surface, (2) and the reservoir being openable, wherein the upper portion and the lower portion define an opening mechanism movable from a closed position to an open position, (3) wherein, with the reservoir opened, the lower and upper portions define an air flow path generally along and across at least a portion of the single reservoir opening of the reservoir from an inlet opening to an outlet opening, such that at least a portion of air in the air flow path enters the reservoir through the single reservoir opening to entrain the dose in the reservoir, and air including entrained dose exits the reservoir through the single reservoir opening and then exits the outlet opening in a direction that is not back toward the inlet opening. 2. The dose delivery device of claim 1, further comprising (4) a diverter portion proximate the outlet to divert the at least a portion of air into a lower part of the reservoir to disperse the dose in the reservoir into air flowing into and out of the reservoir. US patent claim 2 does not disclose a restriction opposite the air inlet. However, Houzego teaches a respiratory device including a restriction opposite the air inlet (42) (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of US patent claim 2 by providing a restriction opposite the air inlet as taught by Houzego in order to provide a maximum air velocity through the pocket portion (Houzego, para [0030]). Regarding claims 28-32, US patent claims 1-4 and 7 discloses the limitations of application claims 28-32. Allowable Subject Matter Claims 27-33 are allowable over the prior art of record; however, claims 27-32 are rejected on the ground of nonstatutory double patenting and therefore claim 33 is objected to for depending from a rejected claim base. The following is an examiner’s statement for reasons for allowance: The closest prior art of the record, Houzego (2007/0181123) discloses a dose cassette for use with an inhaler, comprising: a bottom layer (26) (insert) defining a reservoir (insert (26) contains a respective dose of powder) (para [0155]), wherein at least a portion of the reservoir includes a curved surface (insert (26) is generally cup shaped) (para [0155], fig 9a); wherein the top layer (34) and the bottom layer (26) define at least a portion of an air path (lower arrow) having an air inlet (42) in the opened position to allow air to flow into the reservoir (26) (para [0168]), wherein the air path includes a restriction opposite the air inlet (42) in the opened position (as shown in fig 21a, pocket portion includes a restriction (D) opposite the inlet at C1 (para [0029]), and wherein a diverter is located proximate the restriction and above at least a portion of the reservoir in the opened position to divert at least a portion of air into the reservoir when the air is drawn through the air path (see annotated fig 9(b). However, neither Houzego nor the other prior art of record disclose and the top layer slidably movable relative to the bottom layer from a closed position to an opened position as recited in claim 27, as the device is movable to the opened position by pushing the lower layer (26) outwardly of a through hole (20) of the base (14) (para [0164]). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Rand (2006/0062740), Bulbrook (2008/0142006), Ede (7,588,030), and Anderson (6,065,472) disclose dry powder inhalers including reservoirs configured to move from a closed to an open position Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOUGLAS Y SUL whose telephone number is (571)270-5260. The examiner can normally be reached Monday-Friday 9 am-5:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, TIMOTHY STANIS can be reached at 571-272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DOUGLAS Y SUL/Examiner, Art Unit 3785
Read full office action

Prosecution Timeline

Sep 30, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788918
TRACHEAL VENTILATION DEVICE HAVING OPTIMIZED CUFF TUBE
4y 2m to grant Granted Nov 10, 2026
Patent 12778838
Rapid Cycling Compression Device for the Prevention of Thrombosis
3y 6m to grant Granted Nov 03, 2026
Patent 12779160
CPAP DEVICE AND POWER CONTROL PROGRAM FOR THE SAME
2y 8m to grant Granted Nov 03, 2026
Patent 12773212
DEVICES, SYSTEMS, AND METHODS FOR OCCLUDING AND ALLOWING FLUID ACCESS TO OCCLUSED AREA
4y 1m to grant Granted Oct 27, 2026
Patent 12766041
Wearable sensor
4y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+55.9%)
Low
PTA Risk
Based on 595 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month